| Literature DB >> 27827870 |
Seong-Hoon Yun1, Sung-Won Shin2, Valentin A Stonik3,4, Joo-In Park5.
Abstract
Acute myeloid leukemia (AML) is a heterogeneous myeloid clonal disorder exhibiting the accumulation of immature myeloid progenitors in the bone marrow and peripheral blood. Standard AML therapy requires intensive combination chemotherapy, which leads to significant treatment-related toxicity. The search for new, low toxic marine agents, inducing the generation of ceramide in leukemic cells is a new approach to improve the therapy of leukemia. This review focuses on the metabolism of sphingolipids, the role of ceramide in treating leukemia, and the antitumor activity, related to ceramide metabolism, of some marine metabolites, particularly stichoposides, triterpene glycosides extracted from sea cucumbers of the family Stichopodiidae.Entities:
Keywords: anti-leukemic activity; ceramide; ceramide synthase; sphingomyelinase; stichoposides
Mesh:
Substances:
Year: 2016 PMID: 27827870 PMCID: PMC5128748 DOI: 10.3390/md14110205
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Synthesis and degradation of sphingolipids. GCS; glucosylceramide synthase, SMS; sphingomyelinsynthase, S1PP; sphingosine-1-phosphate phosphatase, Gal; galactose, Glc; glucose, Lac; lactose.
Figure 2Structures of Stichoposides C and D and some other marine inducers of ceramide accumulation in tumor cells.
Figure 3Potential molecular mechanisms of STC-induced (A) and STD-induced apoptosis (B). CerS6: ceramide synthase 6, SMase; sphingomyelinase.